487 related articles for article (PubMed ID: 30094460)
1. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
2. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
3. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
[TBL] [Abstract][Full Text] [Related]
4. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
5.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
6. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
Woff E; Salvatore L; Marmorino F; Genovesi D; Critchi G; Guiot T; Ameye L; Sclafani F; Hendlisz A; Flamen P
J Nucl Med; 2022 Apr; 63(4):549-555. PubMed ID: 34326124
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
10. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
[TBL] [Abstract][Full Text] [Related]
14. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features.
Rahmim A; Bak-Fredslund KP; Ashrafinia S; Lu L; Schmidtlein CR; Subramaniam RM; Morsing A; Keiding S; Horsager J; Munk OL
Eur J Radiol; 2019 Apr; 113():101-109. PubMed ID: 30927933
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.
Lovinfosse P; Polus M; Van Daele D; Martinive P; Daenen F; Hatt M; Visvikis D; Koopmansch B; Lambert F; Coimbra C; Seidel L; Albert A; Delvenne P; Hustinx R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):365-375. PubMed ID: 29046927
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of
Grut H; Dueland S; Line PD; Revheim ME
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
